The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

George G. Zhanel

Department of Medical Microbiology

University of Manitoba

Winnipeg

Manitoba

Canada

[email]@pcs.mb.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada. 1997 - 2012
  • Clinical Microbiology, Health Sciences Centre, 820 Sherbrook St., Winnipeg, Canada. 2003 - 2010
  • Faculties of Medicine and Pharmacy, University of Manitoba; Departments of Medicine and Microbiology, Health Sciences Centre, 820 Sherbrook Street, Canada. 2001
  • University of Manitoba, Health Sciences Centre, Winnipeg, Canada. 2001

References

  1. Oritavancin: mechanism of action. Zhanel, G.G., Schweizer, F., Karlowsky, J.A. Clin. Infect. Dis. (2012) [Pubmed]
  2. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Zhanel, G.G., Adam, H.J., Low, D.E., Blondeau, J., Decorby, M., Karlowsky, J.A., Weshnoweski, B., Vashisht, R., Wierzbowski, A., Hoban, D.J. Diagn. Microbiol. Infect. Dis. (2011) [Pubmed]
  3. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Zhanel, G.G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P.R., Rubinstein, E., Gin, A.S., Hoban, D.J., Karlowsky, J.A. Drugs (2010) [Pubmed]
  4. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Zhanel, G.G., DeCorby, M., Adam, H., Mulvey, M.R., McCracken, M., Lagacé-Wiens, P., Nichol, K.A., Wierzbowski, A., Baudry, P.J., Tailor, F., Karlowsky, J.A., Walkty, A., Schweizer, F., Johnson, J., Hoban, D.J. Antimicrob. Agents Chemother. (2010) [Pubmed]
  5. Overview of seizure-inducing potential of doripenem. Zhanel, G.G., Ketter, N., Rubinstein, E., Friedland, I., Redman, R. Drug. Saf (2009) [Pubmed]
  6. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. Zhanel, G.G., Baudry, P.J., Tailor, F., Cox, L., Hoban, D.J., Karlowsky, J.A. J. Antimicrob. Chemother. (2009) [Pubmed]
  7. In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. Zhanel, G.G., Karlowsky, J.A. Antimicrob. Agents Chemother. (2009) [Pubmed]
  8. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Zhanel, G.G., Voth, D., Nichol, K., Karlowsky, J.A., Noreddin, A.M., Hoban, D.J. J. Antimicrob. Chemother. (2009) [Pubmed]
  9. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Zhanel, G.G., Sniezek, G., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P.R., Rubinstein, E., Gin, A.S., Hoban, D.J., Karlowsky, J.A. Drugs (2009) [Pubmed]
  10. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Zhanel, G.G., Trapp, S., Gin, A.S., DeCorby, M., Lagacé-Wiens, P.R., Rubinstein, E., Hoban, D.J., Karlowsky, J.A. Expert. Rev. Anti. Infect. Ther (2008) [Pubmed]
  11. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Zhanel, G.G., DeCorby, M., Laing, N., Weshnoweski, B., Vashisht, R., Tailor, F., Nichol, K.A., Wierzbowski, A., Baudry, P.J., Karlowsky, J.A., Lagacé-Wiens, P., Walkty, A., McCracken, M., Mulvey, M.R., Johnson, J., Hoban, D.J. Antimicrob. Agents Chemother. (2008) [Pubmed]
  12. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Zhanel, G.G., DeCorby, M., Nichol, K.A., Wierzbowski, A., Baudry, P.J., Karlowsky, J.A., Lagacé-Wiens, P., Walkty, A., Mulvey, M.R., Hoban, D.J. Diagn. Microbiol. Infect. Dis. (2008) [Pubmed]
  13. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Zhanel, G.G., Lam, A., Schweizer, F., Thomson, K., Walkty, A., Rubinstein, E., Gin, A.S., Hoban, D.J., Noreddin, A.M., Karlowsky, J.A. Am. J. Clin. Dermatol (2008) [Pubmed]
  14. Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model. Zhanel, G.G., Baudry, P., Vashisht, V., Laing, N., Noreddin, A.M., Hoban, D.J. J. Antimicrob. Chemother. (2008) [Pubmed]
  15. Comparative review of the carbapenems. Zhanel, G.G., Wiebe, R., Dilay, L., Thomson, K., Rubinstein, E., Hoban, D.J., Noreddin, A.M., Karlowsky, J.A. Drugs (2007) [Pubmed]
  16. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model. Zhanel, G.G., Derkatch, S., Laing, N., Noreddin, A.M., Hoban, D.J. J. Antimicrob. Chemother. (2007) [Pubmed]
  17. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. Zhanel, G.G., Wang, X., Nichol, K., Nikulin, A., Wierzbowski, A.K., Mulvey, M., Hoban, D.J. Int. J. Antimicrob. Agents (2006) [Pubmed]
  18. Tigecycline: a novel glycylcycline antibiotic. Zhanel, G.G., Karlowsky, J.A., Rubinstein, E., Hoban, D.J. Expert. Rev. Anti. Infect. Ther (2006) [Pubmed]
  19. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae. Zhanel, G.G., James, J., Derkatch, S., Laing, N., Noreddin, A.M., Hoban, D.J. J. Antimicrob. Chemother. (2006) [Pubmed]
  20. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Zhanel, G.G., Hisanaga, T.L., Laing, N.M., DeCorby, M.R., Nichol, K.A., Weshnoweski, B., Johnson, J., Noreddin, A., Low, D.E., Karlowsky, J.A., Hoban, D.J. Int. J. Antimicrob. Agents (2006) [Pubmed]
  21. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Zhanel, G.G., Mayer, M., Laing, N., Adam, H.J. Antimicrob. Agents Chemother. (2006) [Pubmed]
  22. Ertapenem: review of a new carbapenem. Zhanel, G.G., Johanson, C., Embil, J.M., Noreddin, A., Gin, A., Vercaigne, L., Hoban, D.J. Expert. Rev. Anti. Infect. Ther (2005) [Pubmed]
  23. The Use of Macrolides in Treatment of Upper Respiratory Tract Infections. Wierzbowski, A.K., Hoban, D.J., Hisanaga, T., Decorby, M., Zhanel, G.G. Curr. Infect. Dis. Rep (2005) [Pubmed]
  24. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Zhanel, G.G., Johanson, C., Laing, N., Hisanaga, T., Wierzbowski, A., Hoban, D.J. Antimicrob. Agents Chemother. (2005) [Pubmed]
  25. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Zhanel, G.G., Hisanaga, T.L., Laing, N.M., DeCorby, M.R., Nichol, K.A., Palatnik, L.P., Johnson, J., Noreddin, A., Harding, G.K., Nicolle, L.E., Hoban, D.J. Int. J. Antimicrob. Agents (2005) [Pubmed]
  26. The Use of Ketolides in Treatment of Upper Respiratory Tract Infections. Zhanel, G.G., Wierzbowski, A.K., Hisanaga, P., Hoban, D.J. Curr. Infect. Dis. Rep (2004) [Pubmed]
  27. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. Zhanel, G.G., Johanson, C., Hisanaga, T., Mendoza, C., Laing, N., Noreddin, A., Wierzbowski, A., Hoban, D.J. J. Antimicrob. Chemother. (2004) [Pubmed]
  28. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Zhanel, G.G., Hoban, D.J., Schurek, K., Karlowsky, J.A. Int. J. Antimicrob. Agents (2004) [Pubmed]
  29. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Zhanel, G.G., Walkty, A., Nichol, K., Smith, H., Noreddin, A., Hoban, D.J. Diagn. Microbiol. Infect. Dis. (2003) [Pubmed]
  30. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. Zhanel, G.G., DeCorby, M., Noreddin, A., Mendoza, C., Cumming, A., Nichol, K., Wierzbowski, A., Hoban, D.J. J. Antimicrob. Chemother. (2003) [Pubmed]
  31. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). Zhanel, G.G., Laing, N.M., Nichol, K.A., Palatnick, L.P., Noreddin, A., Hisanaga, T., Johnson, J.L., Hoban, D.J. J. Antimicrob. Chemother. (2003) [Pubmed]
  32. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Zhanel, G.G., Hisanaga, T., Nichol, K., Wierzbowski, A., Hoban, D.J. Expert. Opin. Emerg. Drugs (2003) [Pubmed]
  33. A critical review of the fluoroquinolones: focus on respiratory infections. Zhanel, G.G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A.S., Embil, J., Smith, H., Hoban, D.J. Drugs (2002) [Pubmed]
  34. Ketolides in the treatment of respiratory infections. Zhanel, G.G., Hoban, D.J. Expert. Opin. Pharmacother (2002) [Pubmed]
  35. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Zhanel, G.G., Roberts, D., Waltky, A., Laing, N., Nichol, K., Smith, H., Noreddin, A., Bellyou, T., Hoban, D.J. J. Antimicrob. Chemother. (2002) [Pubmed]
  36. The ketolides: a critical review. Zhanel, G.G., Walters, M., Noreddin, A., Vercaigne, L.M., Wierzbowski, A., Embil, J.M., Gin, A.S., Douthwaite, S., Hoban, D.J. Drugs (2002) [Pubmed]
  37. Nitrofurantoin is active against vancomycin-resistant enterococci. Zhanel, G.G., Hoban, D.J., Karlowsky, J.A. Antimicrob. Agents Chemother. (2001) [Pubmed]
  38. Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection. Zhanel, G.G. Curr. Infect. Dis. Rep (2001) [Pubmed]
  39. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. Zhanel, G.G., Walters, M., Laing, N., Hoban, D.J. J. Antimicrob. Chemother. (2001) [Pubmed]
  40. Review of macrolides and ketolides: focus on respiratory tract infections. Zhanel, G.G., Dueck, M., Hoban, D.J., Vercaigne, L.M., Embil, J.M., Gin, A.S., Karlowsky, J.A. Drugs (2001) [Pubmed]
  41. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Zhanel, G.G., Saunders, D.G., Hoban, D.J., Karlowsky, J.A. Antimicrob. Agents Chemother. (2001) [Pubmed]
  42. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Zhanel, G.G., Noreddin, A.M. Curr. Opin. Pharmacol (2001) [Pubmed]
  43. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Zhanel, G.G., Karlowsky, J.A., Harding, G.K., Carrie, A., Mazzulli, T., Low, D.E., Hoban, D.J. Antimicrob. Agents Chemother. (2000) [Pubmed]
  44. Comparison of CO2 generation (BACTEC) and viable-count methods to determine the postantibiotic effect of antimycobacterial agents against Mycobacterium avium complex. Zhanel, G.G., Saunders, M.H., Wolfe, J.N., Hoban, D.J., Karlowsky, J.A., Kabani, A.M. Antimicrob. Agents Chemother. (1998) [Pubmed]
  45. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Zhanel, G.G., Kirkpatrick, I.D., Hoban, D.J., Kabani, A.M., Karlowsky, J.A. Antimicrob. Agents Chemother. (1998) [Pubmed]
  46. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Zhanel, G.G., Karlowsky, J.A., Zelenitsky, S.A., Turik, M.A., Hoban, D.J. Antimicrob. Agents Chemother. (1998) [Pubmed]
  47. Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli. Zhanel, G.G., Karlowsky, J.A., Schwartz, B., Jensen, S.B., Hoban, D.J. Chemotherapy (1998) [Pubmed]
  48. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Zhanel, G.G., Karlowsky, J.A., Harding, G.A., Balko, T.V., Zelenitsky, S.A., Friesen, M., Kabani, A., Turik, M., Hoban, D.J. Antimicrob. Agents Chemother. (1997) [Pubmed]
 
WikiGenes - Universities